Trial Site Detail
Drug: |
BIIB021 (CNF2024) |
|||
|---|---|---|---|---|
Trial: |
An Open-Label, 18FDG-PET Pharmacodynamic Assessment of the Effect of BIIB021 in Subjects With Gastrointestinal Stromal Tumors (GIST) Refractory to, Intolerant of, or Not a Candidate for Imatinib and Sunitinib Treatment |
|||
| Conditions: | Gastrointestinal Stromal Tumor | |||
Trial Status: |
Completed |
|||
Vanderbilt-Ingram Cancer Center2220 Pierce Ave. 691 Preston Building |
Principal Investigator: |
Vicki Keedy |
|---|---|
Contact: |
Vanderbilt-Ingram Cancer Center cancer information line 1-800-811-8480. |
Activation Status of this Site: |
Closed |
Notes about this Site: |
|
Vanderbilt-Ingram Cancer Center Website: |
http://www.vicc.org/ct/ |
Navigating the Map
Use the plus (+) and minus (-) controls to zoom in/out.
Click and drag the map or use the arrows to move (pan) the map.
Tip: Click the marker before zooming and the map will stay centered on the marker as you zoom.